Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT02046733 2024-11-08

STIMULI

Phase 2 Completed

222 enrolled 18 charts

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Small Cell Lung Carcinoma

NCT02970981 2024-04-30

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Phase 2 Completed

18 enrolled 8 charts

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Phase 1/2 Completed

73 enrolled 18 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03302234 2023-09-26

KEYNOTE-598

Phase 3 Completed

568 enrolled 20 charts

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Phase 2 Completed

54 enrolled 14 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT03084471 2022-12-22

STRONG

Phase 3 Completed

867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Phase 3 Terminated

481 enrolled 22 charts

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Phase 1 Terminated

6 enrolled 11 charts

Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

NCT01896869 2020-05-19

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Phase 2 Completed

83 enrolled 16 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Pancreatic Neoplasms

NCT00836407 2020-02-24

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Phase 1 Completed

30 enrolled 9 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Pancreatic Neoplasms

Clinical Trials

NEST-1

Tremelimumab

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

IT-01

STIMULI

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

KEYNOTE-598

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

STRONG

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer